Efficacy and Safety of Anti-HER2 Agents in Combination With Chemotherapy for Metastatic HER2-Positive Breast Cancer Patient: A Network Meta-Analysis
BackgroundThe presence of anti-HER2 agents, such as trastuzumab, pertuzumab, and trastuzumab emtansine (T-DM1), significantly improved the prognosis of metastatic HER2-positive (HER2+) breast cancers (BC). However, drug resistance and disease progression are still common. In order to further improve...
Main Authors: | Xiaohui Zhang, Junsheng Leng, Yidong Zhou, Feng Mao, Yan Lin, Songjie Shen, Qiang Sun |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-08-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2021.731210/full |
Similar Items
-
Efficacy of bevacizumab combined with chemotherapy in the treatment of HER2-negative metastatic breast cancer: a network meta-analysis
by: Zhengwu Sun, et al.
Published: (2020-03-01) -
Male HER-2 positive metastatic breast cancer: A case report
by: Na Lin, et al.
Published: (2020-12-01) -
Dual HER2 blockade with lapatinib and trastuzumab in combination with chemotherapy in metastatic gastroesophageal adenocarcinoma
by: E. Von Cheong, et al.
Published: (2021-04-01) -
A retrospective study investigating the rate of HER2 discordance between primary breast carcinoma and locoregional or metastatic disease
by: Chan Arlene, et al.
Published: (2012-11-01) -
Prognostic value of HER3, PTEN and p-HER2 expression in patients with HER2positive breast cancer
by: Sylwia Dębska-Szmich, et al.
Published: (2015-05-01)